Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.
Abstract Categories 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance) 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts) 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects) 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1i. Basic and applied virology (incl in vitro and in vivo models, novel methods) 2a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology) 2b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers and outcome prediction) 2c. Community-acquired respiratory infections 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections 2e. Community acquired skin, soft tissue, bone & joint (excl prostheses) 2f. Community acquired nervous system and other multi-system bacterial infections 2g. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects, excl AMR) 2h. Other intracellular or rare bacteria 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives 3b. Resistance surveillance & epidemiology: Gram-negatives 3c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB) 3d. Resistance mechanisms incl in vitro and in vivo studies, mobile elements (excl TB) 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods) 3f. Clinical outcome of resistant infections (excl trials of new drugs) 3g. Spread of resistance incl reservoirs, ecology, models (excl nosocomial transmission) 3h. Policy aspects of AMR incl societal impact, economics, mitigation 4a. Diagnostic bacteriology – culture based and general microbiology 4b. Lab management (incl automation, information, QC/QA) 4c. MALTI-TOF and other proteomic methods 4d. Molecular diagnostics (incl POCT and syndromic testing) 4e. Strain typing and surveillance (methods other than genomics) 4f. Whole genome sequencing (diagnostic, typing) 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects) 4h. Clinical metagenomics 4i. Bioinformatics tools & pipelines 4j. Other novel diagnostic technologies 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring 5c. New or repurposed antibacterial agents: clinical trials 5d. Antimicrobial stewardship and improved prescribing (incl interventions, decision-support / prediction tools, behavioural aspects) 5e. Safety and adverse effects of treatment 5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling) 6a. Fungal disease epidemiology 6b. Diagnostic mycology (incl molecular) 6c. Antifungal drugs & treatment (incl clinical trials) 6d. Antifungal resistance & susceptibility testing (incl surveillance) 6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis) 7a. Diagnostic parasitology 7b. Antiparasitic susceptibility & resistance 7c. Antiparasitic drugs & treatment 7d. Parasitic disease epidemiology 7e. Travel medicine & migrant health 7f. Food & water safety and environmental health 7g. Global health, public health 7h. Infections in low-resource settings 8a. Intravascular catheter-related infections 8b. Other foreign-body and implant infections 8c. Surgical site infections 8d. Healthcare-associated pneumonia (incl VAP) 8e. Hospital epidemiology, transmission, surveillance & screening (incl. environment) 8f. Other healthcare associated infections (incl CDI) 8g. Infection control interventions and trials (incl. microbiota transplantation) 8h. Disinfection & biocides 8i. Healthcare workers and infection prevention (incl vaccination, behavior and practices) 9a. Microbial pathogenesis & virulence 9b. Host-pathogen interaction (including basic microbiome studies) 9c. Preclinical biofilm studies 9d. Experimental and cellular microbiology 9e. Basic studies using Omics (in vitro and in vivo) 10a. Host genetics: infection susceptibility & immunodeficiency 10b. Clinical epidemiology and treatment of infections in immunocompromised hosts 10c. General vaccinology (incl. policy, social aspects) 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses) 10e. Antibacterial vaccines 10f. Immune response to infection (excl sepsis biomarkers) 10g. Laboratory assessment of immunity and immune resposne to infection 11a. Professional affairs and career development 11b. Publishing, ethics, other academic affairs 11c. Medical education for CM/ID 11d. Digital health and infection (incl AI, data mining, informatics) 11e. Diversity and equality 11f. Advocacy and role of patients 12a. Basic science and virology 12b. Epidemiology- local, regional, global 12c. Clinical features, case management, outcome (incl long-term) 12d. Diagnostics (incl molecular, genomic, rapid tests) 12e. Drug development and treatment modalities (incl. clinical trials) 12f. Immune response (incl immunity assessment, immunomodulation) 12g. Vaccine development, trials, efficacy, policy 12h. Infection control incl healthcare facilities, community settings 12i. Public health policy, mitigation (non-pharmaceutical interventions) 12j. Preparedness and response (COVID and future pandemics) 12k. Other societal aspects (incl. economics) 12l. Virus evolution, variants and impact 21. New drugs 22. Clinical trials 23. COVID-19 24. Outbreaks and public health emergencies other than COVID-19 25. Other
